Analysts Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80

Immuneering Co. (NASDAQ:IMRX) has earned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $12.80.

Several research firms have recently issued reports on IMRX. Morgan Stanley cut shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Immuneering in a research note on Tuesday, January 7th. Finally, Chardan Capital reissued a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a research note on Wednesday.

Immuneering Price Performance

Shares of IMRX stock opened at $2.07 on Thursday. The business has a 50 day simple moving average of $2.05 and a 200 day simple moving average of $1.78. The firm has a market capitalization of $64.27 million, a price-to-earnings ratio of -1.05 and a beta of -0.34. Immuneering has a 12-month low of $1.00 and a 12-month high of $7.68.

Institutional Trading of Immuneering

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new stake in shares of Immuneering during the second quarter valued at approximately $492,000. Renaissance Technologies LLC purchased a new position in Immuneering during the 2nd quarter worth approximately $447,000. HighTower Advisors LLC raised its stake in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Immuneering in the second quarter valued at $67,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Immuneering in the second quarter valued at $44,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.